TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study is a prospective phase II, single arm mono-institutional study conducted in Queen
Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration
of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with
immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.